Acticor Biotech
ALACT | PA
Overview
Corporate Details
- ISIN(s):
- FR0012519668 (+1 more)
- LEI:
- 969500K433EK1G89EV95
- Country:
- France
- Address:
- 82 AVENUE DU MAINE, 75014 PARIS
- Website:
- https://www.acticor-biotech.com
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-01-06 08:00 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 171.0 KB | |
| 2025-01-06 08:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 169.3 KB | |
| 2024-12-19 18:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 205.7 KB | |
| 2024-12-19 18:00 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 214.6 KB | |
| 2024-12-10 18:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 202.1 KB | |
| 2024-12-10 18:00 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 214.1 KB | |
| 2024-11-06 08:30 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 177.1 KB | |
| 2024-11-06 08:30 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 179.2 KB | |
| 2024-11-04 11:46 |
Earnings Release
Inside Information / News release on accounts, results
|
English | 322.8 KB | |
| 2024-11-04 11:46 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 311.2 KB | |
| 2024-10-31 17:45 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 400.7 KB | |
| 2024-10-31 17:45 |
Interim Report
Inside Information / News release on accounts, results
|
English | 464.4 KB | |
| 2024-10-16 17:45 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 289.1 KB | |
| 2024-10-16 17:45 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 223.1 KB | |
| 2024-10-14 08:00 |
Board/Management Information
Informations privilégiées / Autres communiqués
|
French | 275.7 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Herantis Pharma Oyj | Finland | HRTIS | |
| Hiron-Trade Investments & Industrial Buildings Ltd. | Israel | HRON | ||
|
Human Stem Cells Institute PJSC | Russian Federation | ISKJ | |
|
Human Xtensions Ltd. | Israel | HUMX | |
|
Hybrigenics SA | France | ALHYG | |
|
Hyloris Pharmaceuticals SA | Belgium | HYL | |
|
Ikonisys S.A. | France | ALIKO | |
|
IMCB PJSC | Russian Federation | GEMA | |
|
Immunic AG | United States of America | IMUX | |
| Incanthera plc | United Kingdom | N/A |